MedTrace Logo

Prognosis of Coronavirus Disease 2019 (COVID-19) Patients Receiving Receiving Antihypertensives

NCT04357535 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 314

Last updated 2020-08-04

No results posted yet for this study

Summary

Coronavirus disease 2019 (COVID-19) ,caused by the newly identified Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus, has shown substantial global spread affecting over 2 million people and claiming over 120,000 lives to date. In March 2020, the World Health Organization (WHO) declared COVID-19 a global pandemic. The spectrum of manifestations of COVID19 infection ranges from mild flu-like symptoms to severe acute respiratory distress syndrome (ARDS), with an associated fatality rate of 1.4%. The suggested mode of entry of the SARS-CoV-2 into the human respiratory epithelium is through the angiotensin-converting enzyme 2 (ACE2) protein expressed on alveolar cell surfaces. This entry mechanism has sparked the interest of the scientific community. Preliminary epidemiological reports showed an increased risk of ARDS in hypertensive COVID-19 patients. This leads to the hypothesis that hypertensives treated with angiotensin-converting enzyme inhibitor (ACE-I) are at an increased risk of developing complicated COVID-19 infections . Other studies have refuted these claims as unsupported. Studies revealing the up regulation of ACE2 in cells of patients treated with ACE-I or ARBs were the underlying foundation for these claims. This study aims to assess the impact of ACE-I and/or ARBs on the prognosis of patients with COVID19.

Conditions

Interventions

DRUG

Angiotensin-Converting Enzyme Inhibitors (ACE-I) and Angiotensin II Receptor Blockers (ARB)

ACE-I and ARB are a class of blood pressure lowering medications used to manage hypertension.

Sponsors & Collaborators

  • Buraidah Central Hospital

    collaborator OTHER_GOV

  • King Khalid University Hospital

    collaborator OTHER

  • Princess Nourah Bint Abdulrahman University

    collaborator OTHER

  • Hakeam Abdulaziz Hakeam

    lead OTHER

Principal Investigators

  • Hakeam A Hakeam, MSPharm BCPS · King Faisal Specialist Hospital and Research Centre (KFSH&RC)

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-10
Primary Completion
2020-07-01
Completion
2020-08-01
FDA Drug
Yes

Countries

  • Saudi Arabia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04357535 on ClinicalTrials.gov